These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2165 related items for PubMed ID: 9024708

  • 1. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA, Huang L, Berger D, Chang H, Klein-Szanto AJ, Goodrow T, Wood M, Obara T, Heath CW, Lynch H.
    Cancer; 1997 Feb 15; 79(4):700-16. PubMed ID: 9024708
    [Abstract] [Full Text] [Related]

  • 2. Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines.
    Huang L, Lang D, Geradts J, Obara T, Klein-Szanto AJ, Lynch HT, Ruggeri BA.
    Mol Carcinog; 1996 Feb 15; 15(2):85-95. PubMed ID: 8599583
    [Abstract] [Full Text] [Related]

  • 3. p53 mutation without allelic loss and absence of mdm-2 amplification in a transplantable hamster pancreatic ductal adenocarcinoma and derived cell lines but not primary ductal adenocarcinomas in hamsters.
    Okita S, Tsutsumi M, Onji M, Konishi Y.
    Mol Carcinog; 1995 Aug 15; 13(4):266-71. PubMed ID: 7646765
    [Abstract] [Full Text] [Related]

  • 4. Mutational activation of K-ras in nonneoplastic exocrine pancreatic lesions in relation to cigarette smoking status.
    Berger DH, Chang H, Wood M, Huang L, Heath CW, Lehman T, Ruggeri BA.
    Cancer; 1999 Jan 15; 85(2):326-32. PubMed ID: 10023699
    [Abstract] [Full Text] [Related]

  • 5. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
    Bánkfalvi A, Tory K, Kemper M, Breukelmann D, Cubick C, Poremba C, Füzesi L, Lellè RJ, Böcker W.
    Pathol Res Pract; 2000 Jan 15; 196(7):489-501. PubMed ID: 10926327
    [Abstract] [Full Text] [Related]

  • 6. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
    Gorgoulis VG, Rassidakis GZ, Karameris AM, Papastamatiou H, Trigidou R, Veslemes M, Rassidakis AN, Kittas C.
    Mod Pathol; 1996 May 15; 9(5):544-54. PubMed ID: 8733770
    [Abstract] [Full Text] [Related]

  • 7. Human papillomavirus infection in Egyptian esophageal carcinoma: correlation with p53, p21, mdm2, C-erbB2 and impact on survival.
    Bahnassy AA, Zekri AR, Abdallah S, El-Shehaby AM, Sherif GM.
    Pathol Int; 2005 Feb 15; 55(2):53-62. PubMed ID: 15693850
    [Abstract] [Full Text] [Related]

  • 8. p53 mutations and p53, Waf-1, Bax and Bcl-2 expression in field cancerization of the head and neck.
    Lavieille JP, Gazzeri S, Riva C, Reyt E, Brambilla C, Brambilla E.
    Anticancer Res; 1998 Feb 15; 18(6B):4741-9. PubMed ID: 9891551
    [Abstract] [Full Text] [Related]

  • 9. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors.
    Sourvinos G, Spandidos DA.
    Biochem Biophys Res Commun; 1998 Apr 07; 245(1):75-80. PubMed ID: 9535786
    [Abstract] [Full Text] [Related]

  • 10. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
    Belinsky SA, Middleton SK, Picksley SM, Hahn FF, Nikula KJ.
    Radiat Res; 1996 Apr 07; 145(4):449-56. PubMed ID: 8600505
    [Abstract] [Full Text] [Related]

  • 11. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma.
    Rall CJ, Yan YX, Graeme-Cook F, Beauchamp R, Yandell DW, Povoski SP, Rustgi AK.
    Pancreas; 1996 Jan 07; 12(1):10-7. PubMed ID: 8927612
    [Abstract] [Full Text] [Related]

  • 12. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
    Soslow RA, Altorki NK, Yang G, Xie D, Yang CS.
    Mod Pathol; 1999 Jun 07; 12(6):580-6. PubMed ID: 10392633
    [Abstract] [Full Text] [Related]

  • 13. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
    Lu ML, Wikman F, Orntoft TF, Charytonowicz E, Rabbani F, Zhang Z, Dalbagni G, Pohar KS, Yu G, Cordon-Cardo C.
    Clin Cancer Res; 2002 Jan 07; 8(1):171-9. PubMed ID: 11801555
    [Abstract] [Full Text] [Related]

  • 14. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
    Oda Y, Sakamoto A, Satio T, Kawauchi S, Iwamoto Y, Tsuneyoshi M.
    Mod Pathol; 2000 Sep 07; 13(9):994-1004. PubMed ID: 11007040
    [Abstract] [Full Text] [Related]

  • 15. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
    Kawesha A, Ghaneh P, Andrén-Sandberg A, Ograed D, Skar R, Dawiskiba S, Evans JD, Campbell F, Lemoine N, Neoptolemos JP.
    Int J Cancer; 2000 Nov 20; 89(6):469-74. PubMed ID: 11102889
    [Abstract] [Full Text] [Related]

  • 16. [Expression of proteins in p53 (p14ARF-mdm2-p53-p21WAF/CIP1) pathway and their significance in exocrine pancreatic carcinoma].
    Yu GZ, Zhu MH, Ni CR, Li FM, Zheng JM, Gong ZJ.
    Zhonghua Bing Li Xue Za Zhi; 2004 Apr 20; 33(2):130-4. PubMed ID: 15132849
    [Abstract] [Full Text] [Related]

  • 17. Relationship between K-ras mutation and the expression of p21WAF1/CIP1 and p53 in chronic pancreatitis and pancreatic adenocarcinoma.
    Hermanová M, Lukás Z, Kroupová I, Kleibl Z, Novotný J, Nenutil R, Pazourková M, Brázdil J, Kren L, Díte P.
    Neoplasma; 2003 Apr 20; 50(5):319-25. PubMed ID: 14628083
    [Abstract] [Full Text] [Related]

  • 18. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia.
    Seliger B, Papadileris S, Vogel D, Hess G, Brendel C, Störkel S, Ortel J, Kolbe K, Huber C, Huhn D, Neubauer A.
    Eur J Haematol; 1996 Sep 20; 57(3):230-40. PubMed ID: 8898928
    [Abstract] [Full Text] [Related]

  • 19. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J, Blomqvist C, Heikkilä P, Boguslawski KV, Räisänen-Sokolowski A, Bengtsson NO, Mjaaland I, Malmström P, Ostenstadt B, Bergh J, Wist E, Valvere V, Saksela E.
    Clin Cancer Res; 2000 Aug 20; 6(8):3103-10. PubMed ID: 10955790
    [Abstract] [Full Text] [Related]

  • 20. Multiple genetic alterations in hamster pancreatic ductal adenocarcinomas.
    Chang KW, Laconi S, Mangold KA, Hubchak S, Scarpelli DG.
    Cancer Res; 1995 Jun 15; 55(12):2560-8. PubMed ID: 7780969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 109.